Immunological response to Hepatitis B vaccination in obsessive compulsive disorder patients receiving high doses of serotonin reuptake inhibitors

Immunological response to Hepatitis B vaccination in obsessive compulsive disorder patients receiving high doses of serotonin reuptake inhibitors - Hepatitis B vaccination in SRI-treated OCD patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON38586

Enrollment

Registered

2013-09-12

Start date

2014-11-13

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug-induced immunosuppression

Interventions

A full vaccination with Hepatitis B vaccine (Engerix-B) will be performed in all patients, i.e. three doses at months 0, 1 and 6. The immunological response will be determined at three timepoints: p

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Primary diagnosis: obsessive compulsive disorder according to DSM-IV criteria based on a psychiatric interview Age: 18-40 years old Female Body mass index (BMI)

Exclusion criteria

Exclusion criteria: Previous hepatitis B vaccination or hepatitis B infection Suffering from auto-immune disease such as rheumatoid arthritis, lupus erythematosus etc. A weakened immune system, due to conditions such as HIV Kidney and/or liver diseases The use of immunosuppressive medication such as corticosteroids, methotrexate, cyclosporine

Design outcomes

Primary

Measure	Time frame
Primary research variables are 1) antibody titers to hepatitis B virus (anti-HBs) and 2) the cellular (T-cell) response to soluble hepatitis B antigen (HBsAg). The number of cytokine-producing cells (IFNy, TNFa and IL2) will be determined, as well as the HBsAg-specific T-cell proliferation.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)